U.S. Markets open in 47 mins

Ultimovacs ASA (ULTI.OL)

Oslo - Oslo Delayed Price. Currency in NOK
Add to watchlist
61.40-2.10 (-3.31%)
As of 2:21PM CEST. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close63.50
Open63.50
Bid61.40 x N/A
Ask61.70 x N/A
Day's Range61.10 - 63.50
52 Week Range36.00 - 90.60
Volume11,362
Avg. Volume42,720
Market Cap1.965B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.98
Earnings DateMay 11, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Ultimovacs Presents the INITIUM Study Design as a Trial-in-Progress Poster at AACR Annual Meeting 2021
    Business Wire

    Ultimovacs Presents the INITIUM Study Design as a Trial-in-Progress Poster at AACR Annual Meeting 2021

    Ultimovacs ASA ("Ultimovacs", ticker ULTI), announced that it is presenting a poster today on the trial design of its ongoing Phase II INITIUM clinical study evaluating nivolumab and ipilimumab in combination with the Company’s proprietary universal cancer vaccine, UV1, as first line treatment in patients with metastatic malignant melanoma, at the 2021 AACR Annual Meeting, held virtually from April 9 to April 14, 2021.

  • Ultimovacs Starts Clinical Evaluation of Novel TET-Platform with Phase I TENDU Study Investigating Prostate Cancer-Specific Therapeutic Vaccine
    Business Wire

    Ultimovacs Starts Clinical Evaluation of Novel TET-Platform with Phase I TENDU Study Investigating Prostate Cancer-Specific Therapeutic Vaccine

    Ultimovacs ASA ("Ultimovacs", ticker ULTI), today announced the treatment of the first patient in the Phase I TENDU trial, representing the start of clinical evaluation for the Company’s Tetanus-Epitope Targeting (TET)-platform. The platform allows for the production of multiple therapeutic cancer vaccines that can be used to strengthen and increase T cell responses to cancer cells by targeting antigens that are specific to one type of cancer or common to many tumor types. By combining cancer antigens and the vaccine adjuvant in the same molecule, this unique platform can generate vaccine candidates with a beneficial safety and administration profile, presenting an opportunity to treat patients at an early stage of their disease. The TENDU clinical trial, conducted at the Oslo University Hospital, is a first-in-human, dose-escalation study designed to generate initial safety and immune activation data for a prostate cancer-specific therapeutic TET-based vaccine in relapsed prostate cancer patients. The Company expects to provide the first interim, preliminary safety readout from the trial by the end of this year.

  • Ultimovacs ASA: Fourth Quarter 2020 Result Presentation
    Business Wire

    Ultimovacs ASA: Fourth Quarter 2020 Result Presentation

    Ultimovacs ASA ("Ultimovacs", ticker ULTI), a pharmaceutical company developing novel immunotherapies against cancer, announces its fourth quarter 2021 results today. A presentation by the company's management team will take place today on a webcast at 09:00 CET.